Regeneron Pharmaceuticals ((REGN)) announced an update on their ongoing clinical study.
Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Regeneron Pharmaceuticals is conducting a Phase 2 clinical study titled A Phase 2, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Pharmacokinetics and Pharmacodynamics of a Single Dose of REGN5381, an NPR1 Monoclonal Antibody Agonist, in Patients With Chronic Heart Failure With Reduced Ejection Fraction. The study aims to assess the safety, tolerability, and effectiveness of REGN5381, a novel drug for heart failure patients with reduced ejection fraction, examining potential side effects and the body’s response to the drug.
The intervention under investigation is REGN5381, an experimental monoclonal antibody administered via a single dose intravenous infusion. It is designed to improve heart function in patients with heart failure.
The study is interventional, with a randomized, parallel assignment model. It employs quadruple masking, meaning that participants, care providers, investigators, and outcomes assessors are blinded to the treatment allocation. The primary purpose of the study is treatment-focused.
The study began on April 11, 2024, with its primary completion and estimated completion dates yet to be announced. The latest update was submitted on June 24, 2025, indicating ongoing recruitment and progress.
This study update could positively influence Regeneron’s stock performance by enhancing investor confidence in the company’s pipeline. Success in this trial could position Regeneron favorably against competitors in the cardiovascular treatment market, potentially leading to increased market share.
The study is currently ongoing, with further details available on the ClinicalTrials portal.